EUVIMEDEUVIMED entdecken
Vergleichsstudie

Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab

Maya Granot, Nurit Nachum, Alexander Krauthammer, Tal David Berger, Sophia Heiman, Miri Yavzori, Orit Picard, Shomron Ben-Horin, Batia Weiss, Yael Haberman

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.08.071 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Maya Granot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray…. Hauptthemen laut MEDLINE: Infliximab, Adalimumab, Drug Substitution, Crohn Disease. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Israel Science Foundation, Tel Aviv University, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: The development of antibodies to infliximab (ATI) is a major challenge in pediatric inflammatory bowel disease (IBD). This real-world study aimed to identify predictors of ATI, evaluate strategies to overcome ATI, and compare the durability of continuing infliximab (IFX) versus switching to adalimumab (ADA) after ATI development. METHODS: We retrospectively analyzed 194 pediatric IBD patients treated with IFX from 2010 to 2024. ATI titers were measured uniformly before each infusion. Demographic data, disease characteristics, ATI titers, infusion reactions, management strategies, and treatment durability were collected and analyzed. RESULTS: ATI developed in 52 of 194 patients (26.8 %), more frequently in Crohn's disease (31.2 %) than ulcerative colitis (16.1 %, p < 0.01), and was associated with female gender (57.7 % vs. 39.4 %, p = 0.03) and younger age at diagnosis. High-titer ATI (≥8 mcg/ml-eq) correlated with infusion reactions (56.5 % vs. 3.5 %, p < 0.001). ATI was managed with dose/interval adjustment (61.9 %), immunomodulator addition (16.7 %), or both (21.4 %). IFX continuation was successful in 71.4 %, especially in low-titer ATI (92.0 % vs. 41.2 %, p < 0.001). IFX durability after ATI was significantly longer (median 94 months) than ADA after switching (47 months, p < 0.01). CONCLUSIONS: About 27 % of pediatric IBD patients developed ATI to IFX. Personalized management can restore IFX efficacy and provides superior long-term outcomes compared to switching to ADA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabAdalimumabDrug SubstitutionCrohn DiseaseGastrointestinal AgentsColitis, UlcerativeInflammatory Bowel DiseasesHumansFemaleMaleRetrospective StudiesChildAdolescentTreatment OutcomeAntibodies

Stichwörter der Autor:innen

ImmunogenicityPediatric inflammatory bowel disease

Substanzen

InfliximabAdalimumabGastrointestinal AgentsAntibodies

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv…
  • The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel.

Förderung

  • Israel Science Foundation
  • Tel Aviv University
  • European Research Council
  • Leona M and Harry B Helmsley Charitable Trust

Zitieren

APA

Granot, M., Nachum, N., Krauthammer, A., Berger, T. D., Heiman, S., Yavzori, M., Picard, O., Ben-Horin, S., Weiss, B., & Haberman, Y. (2025). Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.08.071

Vancouver

Granot M, Nachum N, Krauthammer A, Berger TD, Heiman S, Yavzori M, et al. Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.08.071

BibTeX
@article{Granot2025,
  author = {Granot, Maya and Nachum, Nurit and Krauthammer, Alexander and Berger, Tal David and Heiman, Sophia and Yavzori, Miri and Picard, Orit and Ben-Horin, Shomron and Weiss, Batia and Haberman, Yael},
  title = {Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.08.071}
}
Kostenlos starten →